gefitinib has been researched along with nutlin-3a in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (nutlin-3a) | Trials (nutlin-3a) | Recent Studies (post-2010) (nutlin-3a) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 698 | 1 | 504 |
| Protein | Taxonomy | gefitinib (IC50) | nutlin-3a (IC50) |
|---|---|---|---|
| Protein Mdm4 | Homo sapiens (human) | 4.6273 | |
| Cellular tumor antigen p53 | Homo sapiens (human) | 1.0388 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.07 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.1832 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Y; He, Q; Lin, G; Lou, J; Ma, J; Wu, Y; Yang, B; Zheng, L; Zhu, H | 1 |
1 other study(ies) available for gefitinib and nutlin-3a
| Article | Year |
|---|---|
Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis.
Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Drug Evaluation, Preclinical; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression; Humans; Imidazoles; Lapatinib; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; RNA, Messenger; Signal Transduction; Smad Proteins; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1; Up-Regulation | 2014 |